Saturday 17 October 2026
Export BNGO’s income statement to Excel — free account
Bionano Genomics, Inc.
BNGO Healthcare Medical Instruments & Supplies
Bionano Genomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.5 million, down 7.37% from fiscal 2024. In the quarter to June 2026, revenue grew 21.4%, EPS grew 67.8%, free cash flow fell 33.9% and total debt fell 1.91%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.25
0.12
−8.76%
Follow BNGO
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 2 | 3 | 3 | 4 | 2 | 3 | 3 | 5 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | (3.93) | (6.75) | 3.07 | 11.81 | 1.93 | (6.39) | (16.38) | (14.26) |
P/S ratio |
0.00 | 0.00 | 3.09 | 1.84 | 37.84 | 46.11 | 15.01 | 1.89 | 0.72 | 0.29 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(16.50) | (39.84) | (9.48) | (16.27) | (6.48) | 9.97 | 0.52 | (13.50) | (37.51) | (31.33) |
Beneish M-Score |
— | (3.06) | (1.51) | (2.44) | 17,663.44 | (0.79) | (2.21) | (5.75) | 5.24 | (3.39) |
P/Operating CF |
(6.97) | (6.97) | (9.07) | (1.98) | (26.58) | (32.36) | (12.09) | (2.29) | (3.40) | (2.00) |
P/B ratio |
0.00 | 0.00 | 3.66 | 5.15 | 9.17 | 2.46 | 1.67 | 0.71 | 0.63 | 0.19 |
Price to Tangible BV |
0.00 | 0.00 | 3.66 | 5.15 | 12.17 | 3.26 | 3.19 | 1.10 | 0.86 | 0.21 |
EV/Sales |
0.00 | 0.00 | 2.52 | 3.96 | 36.91 | 33.17 | 11.58 | (0.44) | 0.63 | (0.12) |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.00 | 0.14 |
EV/Operating CF |
(0.72) | (0.72) | (1.51) | (1.36) | (8.19) | (8.29) | (2.58) | 0.13 | (0.28) | 0.21 |
EV/FCF |
(0.69) | (0.69) | (1.49) | (1.36) | (8.18) | (8.20) | (2.53) | 0.12 | (0.28) | 0.21 |
Quick Ratio |
0.76 | 0.26 | 4.65 | 0.90 | 4.61 | 11.70 | 3.35 | 1.11 | 0.68 | 1.51 |
Current Ratio |
1.15 | 0.43 | 5.09 | 1.07 | 5.23 | 12.47 | 4.38 | 1.40 | 1.06 | 1.98 |
Net Debt/EBITDA |
(0.07) | (0.26) | 0.39 | (0.11) | 0.60 | 3.36 | 0.90 | 0.79 | 0.24 | 1.06 |
Debt/Assets |
44.86% | 66.33% | 36.41% | 66.49% | 27.01% | 0.97% | 1.18% | 1.67% | 4.62% | 4.73% |
Debt/Equity |
(0.24) | (0.13) | 0.89 | 5.56 | 0.47 | 0.01 | 0.01 | 0.04 | 0.10 | 0.08 |
Asset Turnover |
0.54 | 0.76 | 0.69 | 0.37 | 0.19 | 0.08 | 0.08 | 0.14 | 0.21 | 0.38 |
Operating CF/Net income |
1.25 | 0.89 | 1.08 | 0.99 | 0.93 | 0.99 | 0.94 | 0.54 | 0.62 | 0.62 |
Capex/Depreciation |
(1.21) | (0.68) | (0.25) | (0.05) | 0.00 | (0.22) | (0.24) | (0.02) | 0.00 | 0.00 |
Interest Coverage |
(45.03) | (39.29) | (14.78) | (11.32) | (15.30) | (83.17) | (441.94) | (42.05) | — | — |
| 48.65% | 60.31% | 92.27% | (433.64%) | (212.46%) | (38.92%) | (45.21%) | (134.56%) | (170.33%) | (66.15%) | |
| (151.19%) | (187.43%) | (105.85%) | (108.40%) | (90.68%) | (33.11%) | (38.74%) | (89.09%) | (76.97%) | (35.13%) | |
ROIC |
0.00% | 0.00% | (482.56%) | (253.19%) | (185.94%) | (53.45%) | (58.86%) | 0.00% | (352.46%) | (113.43%) |
Return on Tangible Assets |
(347.50%) | 359.08% | (91.21%) | (776.27%) | (96.15%) | (27.76%) | (95.09%) | (366.51%) | (524.33%) | (70.78%) |
Average Days of Receivables |
99.22 | 128.73 | 137.30 | 228.24 | 119.12 | 100.16 | 92.19 | 94.18 | 56.36 | 66.58 |
Research and Development Expense of Revenue |
168.29% | 126.35% | 79.03% | 89.65% | 120.62% | 125.05% | 176.42% | 149.61% | 80.59% | 39.90% |
Selling, General and Administrative Expense of Revenue |
190.65% | 148.13% | 118.50% | 198.98% | 365.38% | 325.29% | 318.67% | 256.83% | 168.49% | 123.30% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.14 | 0.22 | 0.39 | 0.16 | 0.13 | 0.06 |
Share Based Compensation of Revenue |
1.92% | 4.03% | 10.91% | 13.29% | 18.28% | 54.05% | 80.63% | 42.03% | 31.64% | 15.90% |
Graham Net Nets |
0.52 | 0.52 | 0.23 | 0.09 | 0.07 | 0.28 | 0.24 | 0.32 | (0.08) | 1.95 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(68.78%) | (68.78%) | (64.65%) | (160.87%) | (17.17%) | (8.68%) | (31.88%) | (339.47%) | (508.59%) | (311.11%) |
Free Cash Flow Yield |
(153.71%) | (153.71%) | (54.65%) | (159.15%) | (11.93%) | (8.77%) | (30.48%) | (185.81%) | (312.11%) | (197.43%) |
Revenue per Share |
67,928.00 | 2,112.22 | 1,017.01 | 405.18 | 48.84 | 38.90 | 57.56 | 63.47 | 24.21 | 5.24 |
Operating CF per Share |
(234,964.00) | (4,626.18) | (1,690.16) | (1,181.19) | (220.07) | (155.62) | (258.42) | (220.00) | (54.23) | (3.00) |
Capex per Share |
(13,499.00) | (226.18) | (28.11) | (2.44) | 0.00 | (1.78) | (5.14) | (2.97) | (0.08) | 0.00 |
Free Cash Flow per Share |
(248,463.00) | (4,852.36) | (1,718.27) | (1,183.63) | (220.07) | (157.40) | (263.56) | (222.97) | (54.31) | (3.00) |
Cash per Share |
52,496.00 | 227.09 | 1,400.23 | 692.46 | 220.84 | 542.22 | 234.34 | 179.07 | 16.11 | 5.42 |
Shareholders Equity per Share |
(272,590.00) | (11,161.60) | 859.10 | 144.55 | 201.50 | 729.38 | 516.35 | 168.99 | 27.83 | 8.16 |
Interest Debt per Share |
0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(272,590.00) | (11,161.60) | 859.10 | 144.55 | 201.50 | 729.38 | 516.35 | 168.99 | 27.83 | 8.16 |
Free Cash Flow |
(24.85) | (21.84) | (20.28) | (29.59) | (38.31) | (72.75) | (127.30) | (126.87) | (69.02) | (16.34) |
Working Capital |
1.37 | (9.51) | 18.50 | 1.89 | 37.84 | 250.57 | 121.41 | 40.09 | 2.15 | 22.44 |
Capital Expenditures |
(1.35) | (1.02) | (0.33) | (0.06) | — | (0.82) | (2.48) | (1.69) | (0.10) | — |
Net Current Asset Value |
(31.31) | (53.23) | 8.36 | 1.66 | 21.42 | 232.43 | 99.19 | 21.87 | (1.81) | 16.23 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.10 |
Capex to Sales |
0.20 | 0.11 | 0.03 | 0.01 | 0.00 | 0.05 | 0.09 | 0.05 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.28 | 0.50 | 0.74 | 0.58 | 0.30 | 0.36 | 0.58 | 3.88 | 1.74 | 0.59 |
Cash ROIC |
161.59% | 51.41% | (56.81%) | (72.15%) | (42.64%) | (12.30%) | (34.76%) | (62.92%) | (116.23%) | (21.11%) |
Accounts Receivable Turnover |
2.61 | 3.66 | 3.05 | 1.87 | 1.87 | 4.66 | 4.65 | 4.42 | 4.37 | 5.73 |
Accounts Payable Turnover |
2.31 | 3.90 | 4.77 | 3.34 | 2.04 | 2.06 | 1.88 | 2.32 | 3.50 | 2.44 |
Inventory Turnover |
1.80 | 3.45 | 6.31 | 3.00 | 1.70 | 1.80 | 1.04 | 1.01 | 1.79 | 1.85 |
Average Days of Payables |
80.81 | 139.39 | 56.64 | 145.57 | 186.64 | 278.63 | 209.31 | 142.76 | 83.60 | 133.16 |
Days of Inventory on Hand |
183.32 | 102.51 | 44.77 | 185.71 | 211.16 | 320.50 | 496.99 | 314.71 | 133.54 | 129.77 |
Average Receivables |
2.60 | 2.60 | 3.93 | 5.42 | 4.55 | 3.85 | 5.98 | 8.17 | 7.04 | 4.98 |
Average Payables |
1.55 | 1.55 | 1.83 | 2.03 | 2.81 | 6.85 | 11.65 | 11.46 | 8.67 | 6.28 |
Average Inventory |
1.99 | 1.75 | 1.38 | 2.26 | 3.38 | 7.85 | 21.07 | 26.33 | 17.01 | 8.28 |
Average Assets |
12.47 | 12.47 | 17.47 | 27.51 | 45.33 | 218.78 | 342.30 | 260.95 | 145.54 | 75.13 |
Average Common Equity |
(38.74) | (38.74) | (20.04) | 6.88 | 19.35 | 186.10 | 293.26 | 172.78 | 65.77 | 39.90 |
Columns are period end dates